| Literature DB >> 30391117 |
Ai Goto1, Mihoko Hagiwara-Nagasawa2, Hiroko Izumi-Nakaseko3, Kumiko Kitta4, Kiyotaka Hoshiai4, Koki Chiba1, Kentaro Ando5, Yasuki Akie4, Atsuhiko T Naito3, Atsushi Sugiyama6.
Abstract
Although azithromycin can suppress cardiac INa, IKr, IKs, ICa,L and IK1, its onset mechanisms for cardiovascular death have not been fully investigated. We examined electropharmacological effects of azithromycin in intravenous doses of 0.3, 3 and 30 mg/kg using microminipigs under the halothane anesthesia (n = 4), which provided plasma concentrations of 3.1, 11.2 and 120.4 μg/mL, respectively. The low dose did not alter any of the cardiohemodynamic or electrocardiographic variables. The middle dose significantly shortened QT interval for 10-20 min and QTc for 10-30 min. The high dose significantly decreased mean blood pressure for 5-60 min, prolonged QRS width at 20 min, but shortened QT interval for 15-20 min and QTc for 15-30 min (n = 3). Cardiohemodynamic collapse occurred in 1 animal after the start of the high dose infusion, which might be associated with the cardiovascular death in patients with vasomotor dysfunction. Prolongation of QRS width indicates that azithromycin may suppress ventricular INa in vivo, which may unmask latent type of Brugada electrocardiographic genotype. Meanwhile, abbreviation of the QTc might cause potentially lethal, short QT-related, cardiac arrhythmia syndrome. These findings with microminipigs suggest the possible entry point for analyzing the mechanisms of cardiovascular death clinically seen with this antibiotic.Entities:
Keywords: Azithromycin; Brugada syndrome; Hypotension; Microminipigs; Short QT syndrome
Mesh:
Substances:
Year: 2018 PMID: 30391117 DOI: 10.1016/j.jphs.2018.10.003
Source DB: PubMed Journal: J Pharmacol Sci ISSN: 1347-8613 Impact factor: 3.337